A detailed history of Legal & General Group PLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Legal & General Group PLC holds 103,029 shares of FATE stock, worth $171,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
103,029
Previous 103,029 -0.0%
Holding current value
$171,028
Previous $360,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.26 - $7.08 $295,447 - $641,646
90,628 Added 730.81%
103,029 $337,000
Q1 2024

May 14, 2024

SELL
$3.54 - $8.35 $18,510 - $43,662
-5,229 Reduced 29.66%
12,401 $91,000
Q4 2023

Feb 15, 2024

SELL
$1.65 - $3.94 $60,886 - $145,389
-36,901 Reduced 67.67%
17,630 $65,000
Q3 2023

Nov 14, 2023

SELL
$2.02 - $5.04 $52,077 - $129,936
-25,781 Reduced 32.1%
54,531 $115,000
Q2 2023

Aug 14, 2023

SELL
$4.76 - $6.59 $1.21 Million - $1.67 Million
-254,098 Reduced 75.98%
80,312 $382,000
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $909,971 - $2.39 Million
214,616 Added 179.15%
334,410 $1.91 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $119,621 - $289,105
12,132 Added 11.27%
119,794 $1.21 Million
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $297,821 - $510,429
-14,155 Reduced 11.62%
107,662 $2.41 Million
Q2 2022

Aug 22, 2022

BUY
$17.78 - $42.39 $275,181 - $656,070
15,477 Added 14.55%
121,817 $3.02 Million
Q1 2022

May 16, 2022

BUY
$29.67 - $60.28 $145,946 - $296,517
4,919 Added 4.85%
106,340 $4.12 Million
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $334,736 - $450,186
6,997 Added 7.41%
101,421 $5.93 Million
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $2.22 Million - $3.59 Million
37,460 Added 65.76%
94,424 $5.6 Million
Q2 2021

Aug 12, 2021

BUY
$67.25 - $92.52 $364,898 - $502,013
5,426 Added 10.53%
56,964 $4.94 Million
Q1 2021

May 17, 2021

SELL
$72.16 - $117.4 $64,366 - $104,720
-892 Reduced 1.7%
51,538 $4.25 Million
Q4 2020

Feb 12, 2021

BUY
$38.09 - $100.95 $192,430 - $509,999
5,052 Added 10.66%
52,430 $4.77 Million
Q3 2020

Nov 13, 2020

BUY
$30.41 - $40.5 $751,765 - $1 Million
24,721 Added 109.11%
47,378 $1.89 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $11,742 - $20,468
581 Added 2.63%
22,657 $778,000
Q1 2020

May 14, 2020

SELL
$17.28 - $31.88 $153,740 - $283,636
-8,897 Reduced 28.73%
22,076 $491,000
Q4 2019

Feb 13, 2020

BUY
$13.39 - $20.73 $50,091 - $77,550
3,741 Added 13.74%
30,973 $606,000
Q3 2019

Nov 13, 2019

BUY
$15.47 - $22.5 $255,255 - $371,250
16,500 Added 153.75%
27,232 $423,000
Q2 2019

Aug 14, 2019

SELL
$15.61 - $20.44 $15,610 - $20,440
-1,000 Reduced 8.52%
10,732 $218,000
Q1 2019

May 15, 2019

BUY
$13.15 - $18.71 $4,681 - $6,660
356 Added 3.13%
11,732 $206,000
Q4 2018

Feb 15, 2019

BUY
$11.48 - $16.98 $42,694 - $63,148
3,719 Added 48.57%
11,376 $146,000
Q2 2018

Aug 10, 2018

SELL
$9.16 - $13.48 $8,115 - $11,943
-886 Reduced 10.37%
7,657 $87,000
Q1 2018

May 17, 2018

BUY
$6.3 - $13.77 $4,775 - $10,437
758 Added 9.74%
8,543 $83,000
Q4 2017

Feb 13, 2018

BUY
$3.94 - $6.64 $30,672 - $51,692
7,785
7,785 $48,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.